Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new Humana study shows that specialty pharmacy care coordination for cancer patients leads to fewer hospital visits and lower medical costs. The retrospective analysis compared Medicare Advantage members who opted into Humana's CenterWell Oncology Center of Excellence program versus those who didn't. Results were consistent across age groups, genders, and regions — a strong signal that coordinated care works.
A new study from Humana Pharmacy Analytics and Consulting found that cancer patients enrolled in specialty pharmacy care coordination services fared significantly better than those who opted out. The research, published in the Expert Review of Pharmacoeconomics & Outcomes Research, analyzed Humana Medicare Advantage members with Part D coverage who received services through CenterWell's Oncology Center of Excellence (COE) — a program offering personalized clinical support, medication adherence guidance, and mail-order delivery for complex cancer therapies.
The COE model, led by pharmacists, nurses, and specialists, provides follow-up care, side effect monitoring, and adherence support for patients on IV chemotherapy, oral targeted oncolytics, and immunotherapies. Notably, the benefits held up across patient age groups, genders, and geographic regions, suggesting broad applicability.
By the Numbers:
Why it matters: As cancer treatment grows more complex and costly, integrated pharmacy care coordination offers a scalable, data-backed strategy to improve patient outcomes while meaningfully reducing healthcare utilization — a win for patients, payers, and the broader system alike.
